AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02796196 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart
Study NCT02796196 — intervention group
Intervention type: DEVICE
Intervention: Monitoring Device
Description: Wearable physical activity monitoring device
Study NCT02796196 — intervention group
Intervention type: PROCEDURE
Intervention: Physical Therapy
Description: Undergo primarily self-directed physical therapy
Study NCT00903890 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey asking questions regarding the subjects cardiac and general health.
Study NCT03113058 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of γδT cells
Description: Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).
Study NCT04109157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 20-minute pad test
Description: Our 20-minute modified pad test was described previously proposed first by Hahn and Fall and modified by Sand and Ostergard. Each patient's bladder was emptied with a transurethral catheter and filled to the SD amount of sterile water for test. The catheter was removed, and then the patient returned to a standing position with a pre-weighed perineal pad placed on the underwear. The patient was asked to cough 10 times, bear down 10 times, do 10 deep knee bends, jump up and down on the spot 10 times, wash her hands under cold water for 1 minute, walk up and down five stairs 10 times, walk in the hall for 10 minute, and then return for removal of the pad. The pad was then weighed and the net weight was calculated by subtracting from the original dry weight to achieve a measure of the total urine loss during the 20 minute exercise. The pad weight was measured in grams and the accuracy of the scale was 1 gram. The positive pad weight result was defined as more than 1 gram of leakage.
Study NCT03293927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The patient will receive IV fentanyl
Study NCT03293927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The patient will receive IV dexemedetomidine
Study NCT02343939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 60 mg/m\^2 administered intravenously daily on Days 1 to 3 for up to two 14-day induction cycles
Study NCT02343939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m\^2 administered intravenously daily on Days 1 to 7 for up to two 14-day cycles
Study NCT02343939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m\^2 administered intravenously
Study NCT02343939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 administered intravenously or subcutaneously
Study NCT02770794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Discontinue infliximab; receive Infliximab when relapse
Study NCT01200147 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: study withdrawn no details
Study NCT00754104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 0.25 mg/kg. daily.
Study NCT00754104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: 150mg, daily.
Study NCT03131843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol cleansing swab/wipe
Study NCT03131843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No alcohol
Description: No alcohol will be used; alcohol cleansing swab/wipe will be used at a different injection site
Study NCT01438905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small amplitude (Grade IV) mobilization
Description: The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
Study NCT01438905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High velocity, low amplitude (Grade V) mobilization
Description: The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
Study NCT01610089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotope infusion
Description: Control subjects: \[15N2-ureido\] arginine (0.69 mg/kg); \[5-13C,4,4,5,5-D4\] citrulline (0.18mg/kg); 15N citrulline (0.03mg/kg); 15N sodium nitrate (0.003 mg/kg), \[15N\]\[18O3\] potassium nitrate (0.03 mg/kg) and \[18O\]\[13C\]urea (1 mg/kg)over 10 minutes. Followed by a 8-hour infusion of \[15N2-ureido\] arginine (0.69 mg/kg/hr); \[5-13C,4,4,5,5-D4\] citrulline (0.18mg/kg/hr), \[15N\]\[18O3\] potassium nitrate (0.003 mg/kg/hr) and \[18O\]\[13C\]urea (0.1 mg/kg/hr).~Citrullinemia type 1 subjects,\[15N2-ureido\] arginine (4.14 mg/kg); \[5-13C,4,4,5,5-D4\] citrulline (1.08 mg/kg); 15N citrulline (0.18mg/kg); 15N sodium nitrate (0.003 mg/kg), \[15N\]\[18O3\] potassium nitrate (0.03 mg/kg) and \[18O\]\[13C\]urea (1 mg/kg)over 10 minutes, followed by a 8-hour infusion of \[15N2-ureido\] arginine (4.14 mg/kg/hr); \[5-13C,4,4,5,5-D4\] citrulline (1.08 mg/kg/hr), \[15N\]\[18O3\] potassium nitrate (0.003 mg/kg/hr) and \[18O\]\[13C\]urea (0.1 mg/kg/hr).
Study NCT02359955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zero degree teeth
Description: zero degree teeth complete denture was first prescribed to patients in group 1 while patients in group 2 were treated with anatomic teeth complete denture
Study NCT02359955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anatomic teeth
Description: when anatomic teeth complete denture was prescribed to patients in group 1, patients in group 2 were treated with zero degree teeth complete denture
Study NCT03550755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V3-Cervix
Description: Oral tableted preparation containing hydrolyzed tumor antigens derived from peripheral blood and tumor tissue
Study NCT00891020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenous every 4 weeks for 24 weeks
Study NCT00891020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 4 mg/kg every 4 weeks for 24 weeks
Study NCT00891020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonbiologic DMARDs of investigator's choice
Description: Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
Study NCT01124994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic mucosal resection
Description: Confocal laser endomicroscopy will be used to target endoscopic mucosal resection of Barrett's oesophagus-associated neoplasia
Study NCT01256450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buccal soluble film; applied to the buccal mucosa twice daily
Study NCT01256450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: buccal soluble film; applied to the buccal mucosa twice daily
Study NCT00857987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMS Expectorant
Description: Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.
Study NCT00857987 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study NCT01279317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo co-ingestion
Description: 25 ml water co-ingested with a glucose-containing beverage
Study NCT01279317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vinegar co-ingestion
Description: 25 ml vinegar (1 g acetic acid) co-ingested with a glucose-containing beverage
Study NCT01438398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Submucosal endoscopic myotomy with mucosal flap technique
Description: Submucosal Endoscopy with Mucosal Flap (SEMF) technique involves the following: (1) injecting 0.9 % normal saline solution to create a submucosal cushion, (2) tiny cut is made into the cushion, (3) Balloon will be used to dilate the opening and allow passage of endoscope in the submucosal space, (4) Upon direct visualization of the muscle fibers, the doctor will cut the circular layers of the diseased muscles, and (5) Tiny clips will be used to close the tiny cut made earlier.
Study NCT01438398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Submucosal Endoscopic Mucosal Flap (SEMF) technique
Study NCT04120259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Oral Tablet
Description: A biguanide drug used as a first line therapy for Diabetes MellitusType 2
Study NCT04120259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Oral Tablet
Description: A biguanide drug used as a first line therapy for Diabetes MellitusType 2
Study NCT04120259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vinegar
Description: A common herbal/dietary supplement used for centuries as an anti bacterial, cleaning,cooking, anti diabetic agent, to name a few uses.
Study NCT02585947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).
Study NCT01547260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
Study NCT01547260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
Study NCT02892890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Magnetic Resonance Imaging (RMI) evaluation
Study NCT02892890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT00351624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Study NCT00351624 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02887183 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LCZ696 (sacubitril/valsartan)
Description: LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)
Study NCT00765687 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: bisphosphates
Description: any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
Study NCT01632293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive resistance training
Description: The exercise program uses guided progressive resistance training to provide an individualized program of strength training. The progressive resistance training intervention will consist of 12 weeks of guided resistance training twice weekly; in addition, subjects will be instructed to do one day of progressive resistance training at the home weekly.
Study NCT00818766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin or vancomycin
Description: Cefazolin IV every eight hours post-operatively for 48 hours or until all chest tubes were removed, whichever occurred first. Participants under 80 kg received 1 gram of cefazolin and participants who were 80 kg or more received 2 grams of cefazolin. Participants who were penicillin-allergic received 1 gram of vancomycin every 12 hours for 48 hours or until all chest tubes were removed, whichever occurred first.
Study NCT00818766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
Study NCT01540201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional I:E ratio
Description: conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model
Study NCT01540201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I:E = 1:1 ratio
Description: I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
Study NCT02918838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Own Adherence Group
Description: Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
Study NCT02918838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Adherence Group
Description: Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
Study NCT02918838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Study NCT00950183 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Iceman® Cold Therapy unit (djOrtho)
Description: postoperative cold therapy
Study NCT00950183 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ice
Description: postoperative cold therapy
Study NCT03446560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP, conventional follow up
Description: Positive airway pressure to splint the airway and to prevent apneas during sleep. Follow up of patients after initiation of treatment according to clinical routine at the study site. Patients are informed to call or visit the sleep center in case of problems with the CPAP device. At 3 months a follow up visit is scheduled at the sleep center. CPAP compliance data will be downloaded and all patients fill in a number of questionaires related to the CPAP treatment effects on sleep apnea symptoms and health related quality of Life. Mask fitting will be tested.
Study NCT03446560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP, telemedicine based follow up
Description: Follow up of patients by means of a telemedicine solution for surveillance of CPAP treatment, Compliance with and efficacy of CPAP can be followed up by the sleep center personnel on a regular basis. Patients with low compliance and mask fitting problems will be contacted by phone. At the end of the 3 months period a visit at the sleep center will be scheduled only for patients with low compliance, low treatment efficacy, or high mask leakage. All patients will be asked to fill in a number of questionaires related to CPAP treatment effects on sleep apnea symptoms and health related quality of Life.
Study NCT02327520 — intervention group
Intervention type: OTHER
Intervention: Colitis with CDI treatment
Description: All patients will be treated with standard treatment
Study NCT01913730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT01913730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03249012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empiric use of Calcium Carbonate and Calcitriol
Description: Empiric calcium carbonate and calcitriol repletion
Study NCT03249012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTH based Calcium Carbonate and Calcitriol repletion
Description: PTH based treatment
Study NCT03777267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active CR
Description: The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study NCT02637297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Undergo hypnotherapy
Study NCT02637297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02637297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01552213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimum intervention control group
Description: A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
Study NCT01552213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment for glucose intolerance
Description: Diet, exercise glucose monitoring, insulin if necessary
Study NCT00957502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENTact™ Septal Stapler
Description: 1 year aged septal staples
Study NCT00957502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENTact™ Septal Stapler
Description: 18 Month Aged Staples
Study NCT04272268 — intervention group
Intervention type: DEVICE
Intervention: Nasal High flow Oxygen
Description: If the patient is successfully extubated within 4 hours following surgery and meets the post surgery inclusion/exclusion criteria, Nasal high flow oxygen will be administered continuously using a humidifier machine for 5 days. Breathing circuits and nasal cannulae will be connected to the machine to deliver oxygen at 20L/min to the patient.
Study NCT03987308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beinaglutide
Description: Five-week Beinaglutide pump treatment group
Study NCT03987308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Five-week short-term CSII (insulin aspart) treatment group
Study NCT01816594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
Study NCT01816594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
Study NCT01203683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active computer-based training
Description: 8 sessions across 4 weeks.
Study NCT01203683 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Inert computer training
Description: 8 sessions across 4 weeks.
Study NCT02248532 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell therapy
Description: Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes >1.9 mV, and linear shortening \<6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
Study NCT01830556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity